ArticleContemporary clinical trials communications2020
A dietary intervention to improve the microbiome composition of pregnant women with Crohn's disease and their offspring: The MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial design.
Article in Contemporary clinical trials communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Maternal Mental Health and Offspring Brain Development: An Umbrella Review of Prenatal Interventions.Biological psychiatry · 2023Pooled it
- Modifiable lifestyle factors in early life and inflammatory bowel disease risk in two birth cohorts.Journal of Crohn's & colitis · 2026Article
- Maternal and infant gut microbiome.iMeta · 2026Review
- Early-Life Gut Microbiota: Education of the Immune System and Links to Autoimmune Diseases.Microorganisms · 2026Review
- Article
- Anti-inflammatory dietary interventions in inflammatory bowel disease: current insights and future perspectives.Frontiers in nutrition · 2026Article
- Review
- Early life factors, diet and microbiome, and risk of inflammatory bowel disease.Journal of the Canadian Association of Gastroenterology · 2025Article
- Maternal diet in pregnancy and the risk of inflammatory bowel disease in the offspring: a prospective cohort study.The American journal of clinical nutrition · 2025Article
- Review
- Exploring the Early-Life Microbiome and Future Risk of Inflammatory Bowel Disease.Gastroenterology & hepatology · 2023Article
- Metabolomics and lipidomics strategies in modern drug discovery and development.Drug discovery today · 2023Review
- Article
- The microbiota of pregnant women with SARS-CoV-2 and their infants.Microbiome · 2023Article
- Dietary Intake of Pregnant Women with and without Inflammatory Bowel Disease in the United States.Nutrients · 2023Article
- Dietary Interventions in Inflammatory Bowel Disease.Nutrients · 2022Review
- Dietary Patterns and Gut Microbiota: The Crucial Actors in Inflammatory Bowel Disease.Advances in nutrition (Bethesda, Md.) · 2022Review
- Exposomic determinants of immune-mediated diseases: Special focus on type 1 diabetes, celiac disease, asthma, and allergies: The HEDIMED project approach.Environmental epidemiology (Philadelphia, Pa.) · 2022Review
- Food as Treatment of Inflammatory Bowel Diseases.Infection and immunity · 2022Review
- The Concept of Intrauterine Programming and the Development of the Neonatal Microbiome in the Prevention of SARS-CoV-2 Infection.Nutrients · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 2 countries.
Funding
Abstract
Crohn's disease (CD), a type of inflammatory bowel disease (IBD), is a chronic condition of the gastrointestinal tract that is caused by the loss of mucosal tolerance towards the commensal bacteria resulting in inflammatory responses. It has long been postulated that the gut microbiota, a complex and dynamic population of microorganisms, plays a key role in the pathogenesis of IBD. Maternal diagnosis of IBD has been identified as the greatest risk factor for IBD in offspring increasing the odds of developing the disease >4.5-fold. Moreover, babies born to mothers with IBD have demonstrated reduced gut bacterial diversity. There is accumulating evidence that the early life microbiota colonization is informed by maternal diet within the 3rd trimester of pregnancy. While babies born to mothers with IBD would pose an ideal cohort for intervention, no primary prevention measures are currently available. Therefore, we designed the MELODY (Modulating Early Life Microbiome through Dietary Intervention in Pregnancy) trial to test whether the IBD-AID™ dietary intervention during the last trimester of pregnancy can beneficially shift the microbiome of CD patients and their babies, thereby promoting a strong, effective immune system during a critical time of the immune system development. We will also test if favorable changes in the microbiome can lead to a reduced risk of postpartum CD relapse and lower mucosal inflammation in the offspring. This study will help create new opportunities to foster a healthy microbiome in the offspring at high risk of other immune-mediated diseases, potentially reducing their risk later in life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.